Grimes & Company, Inc. X4 Pharmaceuticals, Inc Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding XFOR
# of Institutions
105Shares Held
100MCall Options Held
213KPut Options Held
50.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$5.75 Million2.03% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$5.1 Million0.77% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$3.63 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.44MShares$2.87 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$2.43 Million0.11% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $23.3M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...